PD-L1/CD274 Proteins and Flow Cyt Monoclonal Antibodies

Programmed Death-Ligand 1 (PD-L1), also known as Programmed Cell Death 1 Ligand 1, is encoded by the CD274 gene and is also referred to as B7-H1. It is a classical immune checkpoint molecule broadly expressed on tumor cells and multiple immune-related cell types. By engaging PD-1, PD-L1 suppresses T-cell activation and cytokine production and contributes to immune evasion, making it one of the most important targets in cancer immunology and immune regulation research.

From a disease perspective, PD-L1-related research and therapeutic development remain heavily focused on oncology, especially in areas such as non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, gastric cancer, bladder cancer, renal cell carcinoma, Merkel cell carcinoma, and cutaneous squamous cell carcinoma. The therapeutic landscape around PD-L1 has become increasingly diversified. There are now more than 800 PD-L1-related programs under development globally, spanning monoclonal antibodies, bispecific and multispecific antibodies, ADCs, small-molecule inhibitors, and combination regimens. Marketed and mature commercialized therapies remain centered on monoclonal antibodies, while bispecifics and ADCs represent key growth directions in the current pipeline. More PD-L1-related research and therapeutic development information: “Global Landscape of PD-L1 Targeted Therapies“, “PD-1 vs PD-L1: Mechanistic and Clinical Differences“, and “PD-1/PD-L1: The Central Immune Checkpoint Pathway in Cancer“.

Now, DIMA BIOTECH provides four types of PD-L1 related products, including PD-L1 recombinant proteins, anti-PD-L1 antibodies with Flow Cyt validation, PD-L1 overexpressed stable cell line, and biosimilar reference antibodies. Among of them, the PD-L1 recombinant protein portfolio already covers multiple species including Human, Mouse, Canine, and Cynomolgus, and includes full extracellular domain (ECD) proteins, fragment constructs, and multiple tag formats such as No tag, hFc, mFc, His, and mFc-His. Indexed products currently include Human PD-L1 Protein, Tag Free, Human PD-L1(19-132) Protein, hFc Tag, Human PD-L1(128-238) Protein, hFc Tag, Human PD-L1 Protein, His tag, and Human PD-L1 Protein, mFc-His tag, in addition to mouse, canine, and cynomolgus PD-L1 proteins. These proteins are suitable for receptor-ligand interaction and antibody development studies. The monoclonal antibody also includes products explicitly labeled for ELISA and Flow Cyt, supporting applications such as cell-surface binding analysis, PD-L1 expression profiling, antibody screening, and immune checkpoint assay development.